Explore News By Topic
06/09/2017
PCF study finds that adding a 22-gene test to standard prostate cancer risk groups improves accuracy of patient prognosis
A PCF study presented at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that using a 22-gene test along with standard prostate cancer risk group features vastly improves predictions of how aggressive a patient’s cancer is – enabling clinicians to choose more appropriate therapies and better avoid... Read More
06/07/2017
Cancer patients who self-report symptoms to their doctors on a weekly basis live five months longer
A provocative study at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting reported that metastatic cancer patients who self-reported their symptoms to their doctors on a weekly basis lived 5.2 months longer on average, likely due to more proactive symptom management. Dr. Ethan Basch, a medical oncologist at... Read More
06/06/2017
Abiraterone and Enzalutamide equivalent as first-line therapy in metastatic hormone therapy- resistant prostate cancer
A clinical trial reported on at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that men who develop metastatic hormone therapy-resistant prostate cancer (mHRPC) have similar outcomes if prescribed either abiraterone or enzalutamide. Abiraterone and enzalutamide are two hormonal therapies that can be used as first line... Read More
06/06/2017
Your Best Weapon Against Metastatic Prostate Cancer May Be a Genetic Counselor
Mark Meerschaert is alive today because of a genetic counselor, a medical oncologist in Seattle named Heather Cheng, M.D., Ph.D. (You can read more about Mark’s story here.) Less than a year ago, Mark was desperate: hormonal therapy had failed, and traditional chemotherapy was not going to save his life. ... Read More
06/03/2017
Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival
ASCO Perspective “For men who are diagnosed with advanced prostate cancer, treatment has evolved into more effective approaches, first with chemotherapy and now with abiraterone,” said Sumanta Kumar Pal, MD, ASCO Expert. “This is good news because using abiraterone could help many people live longer with fairly few additional side... Read More
06/03/2017
2017 ASCO Meeting: Results from the LATITUDE Study
If you have just been diagnosed with metastatic prostate cancer and your doctor wants to start you on ADT (androgen deprivation therapy, such as Lupron), which shuts off the supply of testosterone and other male hormones, ask for abiraterone as well. It could extend your life for years. But wait,... Read More
06/01/2017
Prostate Cancer Foundation and Major League Baseball Launch Annual Home Run Challenge to Defeat Prostate Cancer
LOS ANGELES, June 1, 2017 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Major League Baseball (MLB) are launching the annual Home Run Challenge on June 1, and running through Father's Day, June 18, in all 30 MLB ballparks throughout the United States and Canada. For the first time, all MLB... Read More
05/26/2017
FDA approves first precision medicine for the treatment of cancers with certain genetic defects, including prostate cancer
On May 23, 2017, the field of precision medicine achieved a major milestone with the FDA’s first ever approval of a cancer therapy based entirely on a tumor’s unique characteristics and not where the tumor developed in the body. In other words, while therapies to date have been approved for... Read More
05/22/2017
Prostate cancer cells that commit identify fraud
A new study reported at the 2017 American Association for Cancer Research (AACR) Annual Meeting identified new mechanisms and treatment approach for an aggressive subtype of AR-therapy resistant prostate cancer. Prostate cancers are fueled by male hormones called androgens. These growth signals are transmitted to cancer cells through the androgen... Read More
05/17/2017
Many vs Cancer, the First Major Global Crowdfunding Initiative to Defeat Prostate Cancer, Launches Today
LOS ANGELES, May 17, 2017 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the launch of Many vs Cancer (MvC), its first global fundraising initiative that is harnessing the collective power of those touched by prostate cancer with the scientists working to defeat it. MvC aims to empower patients,... Read More